Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | PTGFR | P43088 | 3/20 | 0.46 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637308 | 1.00 | EGFR (1.00) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL14148738 | 0.81 | EGFR (0.69) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL15432136 | 0.81 | EGFR (0.69) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL17508764 | 0.81 | EGFR (0.69) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL27176782 | 0.81 | EGFR (0.69) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL17508763 | 0.81 | EGFR (0.69) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL5893730 | 0.78 | EGFR (0.64) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL6167022 | 0.78 | EGFR (0.64) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL6167026 | 0.78 | EGFR (0.64) | EGFRPTGER3PTGER2PTGDRTBXA2R | |
| SCHEMBL4417309 | 0.78 | EGFR (0.64) | EGFRPTGER3PTGER2PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160201111-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | UNITED STATES GOVERNMENT | 2016-07-14 | — | — | US | claimed |
| US-11561188-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200157598-A1 | METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION | ICAGEN, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10577642-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180237823-A1 | METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION | UNITED STATES GOVERNMENT | 2018-08-23 | — | — | US | disclosed |
| US-9976172-B2 | Method and apparatus for measuring protein post-translational modification | ICAGEN, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160201111-A1 | Method and Apparatus for Measuring Protein Post-Translational Modification | UNITED STATES GOVERNMENT | 2016-07-14 | — | — | US | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-8697350-B2 | Biomarker combinations for colorectal cancer | DIAGNOPLEX (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| WO-2007056135-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056162-A2 | METHODS OF TREATING CANCERS WITH SAHA, CARBOPLATIN, AND PACLITAXEL AND OTHER COMBINATION THERAPIES | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056244-A2 | METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056232-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006110608-A2 | COMPOSITIONS AND METHOD FOR INCREASING THE EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-0850055-B1 | PROTEIN TYROSINE KINASE INHIBITORS FOR TREATING OSTEOARTHRITIS | OSTEOARTHRITIS SCIENCES INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050043264-A1 | Methods of inhibiting neurodegenerative disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2005-02-24 | — | — | US | disclosed |
| US-6552066-B1 | Administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor, with the proviso that protein tyrosine kinase inhibitor is not a flavone, isoflavone, hymenialdisine or its analog | OSTEOARTHRITIS SCIENCES, INC. LIQUIDATING TRUST, RICHARD G. MCKENZIE, TRUSTEE, THE | 2003-04-22 | — | — | US | disclosed |
| US-20030060515-A1 | Protein tyrosine kinase inhibitors for treating osteoarthritis | THE OSTEOARTHRITIS SCIENCES, INC. LIQUIDATING TRUST (US) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060515-A1 | Protein tyrosine kinase inhibitors for treating osteoarthritis | MUSK, SRC, GRB2 | EGFR 237/4885PTGER3 3513/4885PTGER2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.